Skip to main content
PEPTARA LABS
Get Started

Retatrutide Half Life

Retatrutide Half Life

Published by · Updated · How we research and check our pages

The short answer

The retatrutide half life is reported as approximately 6 days in published clinical research, a value measured in days rather than hours (Jastreboff et al., 2023; Coskun et al., 2022).

This page is general educational information, research-use framing only, not medical advice. Research-grade retatrutide is supplied for laboratory research only, not for human use.

What is the retatrutide half life?

The retatrutide half life is approximately 6 days, based on published pharmacokinetic data (Jastreboff et al., 2023; Coskun et al., 2022).

To state it plainly: the phase 2 obesity trial reported that retatrutide has a half-life of about 6 days (Jastreboff et al., 2023). The earlier phase 1 work characterized the same slow clearance (Coskun et al., 2022).

A half-life measured in days, not hours, is the headline pharmacokinetic finding. Human pharmacokinetic data on retatrutide is still relatively recent, so the roughly 6-day figure should be read as the value reported in early-phase and phase 2 literature rather than a long-settled constant. Even so, the number is published and citable, not withheld.

What does a 6-day half-life mean?

A half-life near 6 days means the concentration in the blood falls by half about every 6 days, so retatrutide clears slowly, over weeks rather than hours (Jastreboff et al., 2023).

Half-life is the time for the concentration in the body to fall by half. With a 6-day half-life, about half of the compound is still present 6 days after administration and about a quarter after 12 days. Retatrutide was built as one molecule that engages three receptors, GIP, GLP-1, and glucagon (Jastreboff et al., 2023).

For vial mixing figures, see a reconstitution calculator on peptidesvietnam.com.

What does the phase 2 pharmacokinetic profile report?

The trial reported dose-proportional pharmacokinetics and a half-life of approximately 6 days (Jastreboff et al., 2023).

Pharmacokinetic parameterWhat the research reportsSource
Half-lifeApproximately 6 daysJastreboff et al., 2023
Dose proportionalityDose proportional across studied dosesJastreboff et al., 2023

Dose proportional means the half-life did not swing widely with the size of the dose, so the clearance behavior stays consistent across the range studied. These figures describe controlled research.

How does retatrutide's half-life compare with other long-acting agents?

All three leading incretin-class agents are long-acting, with half-lives measured in days.

CompoundReceptor targetsReported half-life
RetatrutideGIP, GLP-1, glucagonAbout 6 days (Jastreboff et al., 2023)
TirzepatideGIP, GLP-1About 5 days (Jastreboff et al., 2022)
SemaglutideGLP-1About 7 days (Wilding et al., 2021)

The through-line is a half-life measured in days. Retatrutide adds glucagon-receptor activity to the GIP and GLP-1 mechanism, but its multi-day clearance is familiar for the class (Jastreboff et al., 2023). For context on efficacy rather than pharmacokinetics, the highest dose group in the phase 2 trial was associated with up to about 24.2 percent weight change at 48 weeks (Jastreboff et al., 2023).

How quickly does retatrutide clear after administration ends?

Slowly. Because clearance runs on a roughly 6-day half-life, retatrutide takes several weeks to clear after administration ends, and research on this class reports that weight tends to return once drug exposure ends (Aronne et al., 2024).

As a general property of drug clearance, about four to five half-lives pass before levels fall close to zero, which for a roughly 6-day half-life works out to about a month.

After tirzepatide was withdrawn in SURMOUNT-4, participants regained weight (Aronne et al., 2024). The STEP 1 extension showed a similar pattern after semaglutide was stopped (Wilding et al., 2022). Part of why is adaptive thermogenesis, the body's tendency to defend a higher weight set point after loss (Rosenbaum and Leibel, 2010). Retatrutide-specific withdrawal data should be read from its own trial reports as they mature, since human data on this compound is still early.

Retatrutide Half Life: FAQ

What is the reported half-life of retatrutide?

Approximately 6 days, according to published clinical research (Jastreboff et al., 2023; Coskun et al., 2022). Human pharmacokinetic data for the compound is still recent, so treat the roughly 6-day figure as the value reported in early trials.

Why does the half-life matter?

Half-life is the time it takes for the concentration in the blood to fall by half, so it sets how long a compound stays in circulation. At about 6 days, retatrutide clears over weeks rather than hours (Jastreboff et al., 2023).

How long does retatrutide stay in the body after administration ends?

Several weeks. With a half-life around 6 days, levels fall by half about every 6 days, so multiple weeks pass before the drug is largely cleared (Jastreboff et al., 2023).

Is retatrutide the same as tirzepatide?

No. Tirzepatide targets two receptors, GIP and GLP-1 (Jastreboff et al., 2022). Retatrutide targets three, adding glucagon (Jastreboff et al., 2023).

Is retatrutide approved?

No. Retatrutide is investigational and has no regulatory approval.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.

Chat with us